Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Still a Buy?

Pharming Group (NASDAQ:PHAR) shares saw strong trading volume on Monday . 6,820 shares were traded during trading, an increase of 40% from the previous session’s volume of 4,880 shares.The stock last traded at $8.47 and had previously closed at $8.52.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Oppenheimer reduced their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, October 24th.

Pharming Group Stock Down 2.4 %

The company has a market capitalization of $551.46 million, a price-to-earnings ratio of -31.27 and a beta of 0.13. The firm’s 50-day simple moving average is $8.15 and its 200-day simple moving average is $8.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.